Boehringer seeks expanded EU approval for anticoagulant

06/25/2013 | Reuters

Boehringer Ingelheim filed an application with the European Medicines Agency seeking wider approval of its oral anticoagulant Pradaxa, or dabigatran. The firm wants the drug to be approved for treatment of deep vein thrombosis and pulmonary embolism, and for the prevention of recurrent DVT and PE.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC